Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGTC-402 in Patients With CNGA3-Related Achromatopsia
NCT02935517Phase 2Active, not recruiting
- Sponsor
- Beacon Therapeutics
- Start
- Aug 2017
- Primary completion
- Aug 2022
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
Phase 2, open-label trial of AGTC-402 in achromatopsia (ACHM) (8 arms), sponsored by Beacon Therapeutics. Primary endpoint: Adverse events at 1 year. Started Aug 2017; status: active, not recruiting.
02
Drugs
AGTC-402
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on NCT02935517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935517.